Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Enterprise Value to FCFF (EV/FCFF) 

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

Merck & Co. Inc., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income attributable to Merck & Co., Inc. 17,117 365 14,519 13,049 7,067
Net income attributable to noncontrolling interests 16 12 7 13 15
Net noncash charges 8,002 14,834 7,351 3,899 7,761
Net changes in assets and liabilities (3,667) (2,205) (2,782) (3,839) (4,590)
Net cash provided by operating activities 21,468 13,006 19,095 13,122 10,253
Interest paid, net of tax1 1,117 220 827 693 663
Capital expenditures (3,372) (3,863) (4,388) (4,448) (4,684)
Free cash flow to the firm (FCFF) 19,213 9,363 15,534 9,367 6,232

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Merck & Co. Inc. suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Merck & Co. Inc. FCFF decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Interest Paid, Net of Tax

Merck & Co. Inc., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Effective Income Tax Rate (EITR)
EITR1 14.10% 80.00% 11.70% 11.00% 19.40%
Interest Paid, Net of Tax
Interest paid, before tax 1,300 1,100 937 779 822
Less: Interest paid, tax2 183 880 110 86 159
Interest paid, net of tax 1,117 220 827 693 663

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 See details »

2 2024 Calculation
Interest paid, tax = Interest paid × EITR
= 1,300 × 14.10% = 183


Enterprise Value to FCFF Ratio, Current

Merck & Co. Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 222,381
Free cash flow to the firm (FCFF) 19,213
Valuation Ratio
EV/FCFF 11.57
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc. 18.66
Amgen Inc. 14.82
Bristol-Myers Squibb Co. 8.94
Danaher Corp. 27.48
Eli Lilly & Co. 192.52
Gilead Sciences Inc. 13.60
Johnson & Johnson 17.95
Pfizer Inc. 13.65
Regeneron Pharmaceuticals Inc. 15.52
Thermo Fisher Scientific Inc. 21.55
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 22.03
EV/FCFF, Industry
Health Care 22.20

Based on: 10-K (reporting date: 2024-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Merck & Co. Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 254,436 354,322 296,532 217,996 212,628
Free cash flow to the firm (FCFF)2 19,213 9,363 15,534 9,367 6,232
Valuation Ratio
EV/FCFF3 13.24 37.84 19.09 23.27 34.12
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc. 20.05 14.89 12.15 13.18 13.95
Amgen Inc. 15.35 22.22 16.01 15.82 14.51
Bristol-Myers Squibb Co. 9.94 9.14 13.87 10.52 11.63
Danaher Corp. 28.93 36.34 25.74 28.25 30.66
Eli Lilly & Co. 200.93 655.33 59.14 38.37 39.01
Gilead Sciences Inc. 14.50 13.41 13.58 8.42 13.60
Johnson & Johnson 18.16 19.30 23.80 21.25 20.75
Pfizer Inc. 15.33 32.24 9.15 8.40 21.74
Regeneron Pharmaceuticals Inc. 19.30 23.99 17.96 9.81 25.74
Thermo Fisher Scientific Inc. 26.13 28.85 31.61 33.14 26.14
Vertex Pharmaceuticals Inc. 29.45 16.68 22.47 16.00
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 23.57 27.24 17.95 16.12 19.74
EV/FCFF, Industry
Health Care 23.63 24.95 17.94 17.18 18.55

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 See details »

2 See details »

3 2024 Calculation
EV/FCFF = EV ÷ FCFF
= 254,436 ÷ 19,213 = 13.24

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Merck & Co. Inc. EV/FCFF ratio increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.